TMDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TransMedics Group Inc (TMDX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown impressive financial growth in the latest quarter, the lack of strong trading signals, insider selling trends, and mixed analyst sentiment suggest waiting for a better entry point. The pre-market price increase of 1.70% is not enough to justify immediate action given the broader context.
The MACD is positive and contracting, indicating a potential upward momentum. RSI is neutral at 53.198, and moving averages are converging, showing no clear trend. The current pre-market price of $115.14 is close to the pivot point of $114.121, with resistance at $119.034 and support at $109.209. Overall, the technical indicators suggest a neutral trend.
The launch of the Controlled Hypothermic Organ Preservation System (CHOPS) at the ISHLT Annual Meeting could enhance the company's clinical trial capabilities and market position. Additionally, the company reported strong financial growth in Q4 2025, with revenue up 32.18% YoY and net income up 1436.87% YoY.
The stock has a 60% chance of declining by 6.2% over the next month based on historical patterns.
In Q4 2025, TransMedics reported revenue growth of 32.18% YoY to $160.76M, net income growth of 1436.87% YoY to $105.38M, and EPS growth of 1257.89% YoY to $2.58. However, the gross margin dropped slightly by -1.86% YoY to 58.11%. The financial performance shows strong growth but also highlights potential margin pressures.
Analyst sentiment is mixed. Recent ratings include Evercore ISI lowering its price target to $118 while maintaining an Outperform rating, and Stifel raising its target to $130 but maintaining a Hold rating. Other analysts like Piper Sandler and Oppenheimer have raised their targets significantly, citing strong financial performance and future growth potential. However, the mixed ratings and price target changes indicate uncertainty.
